このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Pneumonia After Cardiovascular Surgery With Artificial Intelligence

Hospital-acquired Pneumonia After Cardiovascular Surgery (CS): the Prediction and Assessment of Long-term Cardiovascular and Pulmonary Outcomes With Artificial Intelligence (AI) - (PNEUMONIA-CS-AI)

This multicenter, prospective, observational study aims to address two primary objectives.

The first objective is to demonstrate that hospital-acquired pneumonia (nosocomial pneumonia) following cardiac surgery can be predicted using artificial intelligence (AI), and to develop a personalized risk calculator for its development.

The second objective is to demonstrate that hospital-acquired pneumonia can serve as a risk factor for a 1-year composite cardiovascular and pulmonary outcome after cardiac surgery, and to develop a personalized risk calculator for this composite outcome.

The composite outcome will include the occurrence of any of the following events:

  • Respiratory death
  • Hospitalization for respiratory diseases
  • Development of oxygen dependence
  • New-onset asthma, COPD, or interstitial lung disease
  • Initiation or intensification of bronchodilator or corticosteroid therapy
  • Cardiovascular death
  • Acute myocardial infarction
  • Unstable angina
  • Myocardial revascularization
  • Acute ischemic stroke
  • Transient ischemic attack
  • Acute heart failure
  • Hospitalization for decompensated heart failure
  • New-onset atrial fibrillation or ventricular tachycardia
  • Initiation or intensification of antiarrhythmic therapy Both objectives will be addressed using artificial intelligence technologies applied during the data analysis phase.

This is a non-interventional study. Patient evaluation and treatment are conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use in the Russian Federation) medical or diagnostic procedures will be performed during this study.

調査の概要

状態

募集

条件

詳細な説明

Hospital-acquired pneumonia (nosocomial pneumonia) is one of the most common complications following cardiac and/or vascular surgery, with an incidence reaching up to 37% after certain types of procedures. This complication is associated with prolonged hospital stays, increased healthcare costs, and higher mortality rates both during hospitalization and within 5 years post-surgery. To determine the necessity of implementing additional personalized preventive measures against pneumonia, it is clinically valuable to assess the probability of its development in each individual patient. A medical risk calculator, which enables the calculation of an individual's risk of developing pneumonia, can serve as a supportive tool for clinical decision-making.

This is an observational study. Patient evaluation and treatment will be conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use) medical or diagnostic methods will be utilized in this study.

The study involves the systematic collection of data from the medical records of patients who undergo cardiac and/or vascular surgery during their current hospitalization. These data will be analyzed using artificial intelligence (AI) technologies, including machine learning methods such as gradient boosting, random forest, neural networks, Bayesian networks, and others.

This is a multicenter study involving three participating centers: Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk State University, and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases.

In phase 1, data will be collected from at least 400 patients undergoing cardiac surgery at a single center (Tomsk National Research Medical Center of the Russian Academy of Sciences). An anonymized database will be created, including the following parameters:

  • Demographic and anthropometric characteristics (age, sex, height, weight, body mass index)
  • Smoking status, including duration and intensity (pack-years)
  • Comorbidities, including chronic obstructive pulmonary disease (COPD), diabetes mellitus, chronic kidney disease (CKD), prior myocardial infarction, and atrial fibrillation
  • Preoperative left ventricular ejection fraction (LVEF)
  • Preoperative pulmonary function test (PFT) parameters
  • Preoperative length of hospital stay
  • Intraoperative variables, including type of surgery, use and duration of cardiopulmonary bypass (CPB), volume of blood loss, blood component transfusion, duration of mechanical ventilation, and other relevant surgical details
  • Perioperative laboratory data, including hemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, serum creatinine, and creatine phosphokinase (CPK) Subsequently, the occurrence or non-occurrence of hospital-acquired pneumonia will be documented within 30 days post-surgery. Additionally, other relevant clinical data regarding the course of the postoperative period will be collected.

Phase 2 will be conducted jointly by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on data processing and analysis. This phase will include:

  • Data integrity assessment and quality control
  • Missing data imputation (handling of missing values)
  • Development of predictive models for hospital-acquired pneumonia using multivariate binary logistic regression (SPSS version 26.0) and machine learning algorithms, including Bayesian networks, decision trees, random forest, gradient boosting, and recurrent neural networks (RNN).

Phase 3, also performed by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, involves the evaluation and comparison of the developed predictive models. The models will be compared based on key performance metrics:

  • Accuracy, sensitivity, and specificity
  • Interpretability
  • Robustness to overfitting and data incompleteness Based on this evaluation, the preferred predictive model for hospital-acquired pneumonia demonstrating optimal performance characteristics will be selected.

Phase 4 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University) will focus on the development of a universal medical risk calculator. This tool will determine the individual probability of developing hospital-acquired pneumonia following any type of cardiac and/or vascular surgical intervention. The calculator will be constructed by selecting key predictors and evaluating the feature weights (coefficients) derived from the best-performing predictive model identified in Phase 3.

Phase 5 will involve the internal validation of the developed risk calculator. This phase will consist of the following steps:

  • Prospective enrollment of an additional 200 patients into the observational study at the primary center (Tomsk National Research Medical Center of the Russian Academy of Sciences).
  • Preoperative assessment of the individual risk (probability) of hospital-acquired pneumonia for each patient using the newly developed calculator.
  • Surgical intervention followed by a 30-day postoperative observation period.
  • Calibration and performance analysis by comparing the pre-test (predicted) probability of pneumonia with the actual observed postoperative outcomes.

Phase 6 will involve the external validation of the developed medical risk calculator across 1 to 3 cardiovascular surgery centers. Each participating center will conduct an evaluation identical to Phase 5, prospectively enrolling data from at least 100 patients. Initially, the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases will join the study, with the potential inclusion of additional medical centers at a later stage.

Phase 7 (conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and the Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases) aims to evaluate the impact of hospital-acquired pneumonia on the development of clinical outcomes within 12 months post-cardiac surgery. These outcomes include:

  • Primary composite cardiovascular and pulmonary outcome
  • Secondary composite pulmonary outcome
  • Secondary composite cardiovascular outcome

This phase will be conducted by gathering follow-up data from enrolled patients or their next of kin via in-person visits, telephone interviews, medical record reviews, or centralized electronic healthcare registries. Data will be collected on whether patients experienced any of the following events within 12 months after surgery:

  • Pulmonary / Respiratory Events: Respiratory death, hospitalization for respiratory diseases, development of oxygen dependence, new-onset asthma, COPD, or interstitial lung disease, and initiation or intensification of bronchodilator or corticosteroid therapy.
  • Cardiovascular Events: Cardiovascular death, acute myocardial infarction, unstable angina, myocardial revascularization, acute ischemic stroke, transient ischemic attack (TIA), acute heart failure, hospitalization for decompensated heart failure, new-onset atrial fibrillation or ventricular tachycardia, and initiation or intensification of antiarrhythmic therapy.

Phase 8 will be conducted by Tomsk National Research Medical Center of the Russian Academy of Sciences and Tomsk State University, focusing on the processing and analysis of the 12-month follow-up data. This final phase will include:

  • Data integrity assessment and quality control.
  • Missing data imputation for the long-term follow-up variables.
  • Comparative analysis of the incidence of cardiovascular and pulmonary events within 12 months post-surgery between patients who developed hospital-acquired pneumonia during the early postoperative period and those who did not.
  • Development of predictive models for the study's composite endpoints, utilizing both standard statistical methods and artificial intelligence (AI) / machine learning algorithms.

研究の種類

観察的

入学 (推定)

700

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Alla A. Boshchenko, MD, PhD, DSc
  • 電話番号:+ 7 (3822)-909055
  • メール:bosh@cardio-tomsk.ru

研究連絡先のバックアップ

研究場所

      • Tomsk、ロシア
        • 募集
        • Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Patients of 18 years and older after cardiac and/or vascular surgical intervention during the current hospitalization

説明

Inclusion Criteria:

  • Age ≥ 18 years;
  • Cardiac and/or vascular surgical intervention during the current hospitalization;
  • Signed informed consent from the patient for the use of their anonymized data for scientific purposes.

Exclusion Criteria:

  • Use of systemic antibacterial drugs within 30 days prior to the surgical intervention;
  • Prescription of systemic antibacterial drugs during the hospitalization period for any indication other than hospital-acquired pneumonia;
  • HIV infection.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Patients after cardiovascular surgery
Patients of 18 years and older, after cardiac and/or vascular surgical intervention during the current hospitalization, who signed informed consent for the use of their anonymized data for scientific purposes
該当なし - 観察研究

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Hospital acquired pneumonia
時間枠:Within 30 days post-surgery
Occurrence of hospital-acquired pneumonia
Within 30 days post-surgery
Composite cardiovascular and pulmonary endpoint
時間枠:12 months post-surgery
Occurrence of the composite cardiovascular and pulmonary endpoint
12 months post-surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Non-pneumonia postoperative complications
時間枠:Within 30 days post-surgery
Incidence of non-pneumonia postoperative complications (surgical site infections, cardiac events, etc.)
Within 30 days post-surgery
Composite Pulmonary Outcome
時間枠:12 months post-surgery

Incidence of the Composite Pulmonary Outcome:

Respiratory death; Hospitalization due to respiratory diseases; New-onset oxygen dependence; New-onset asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease (ILD); Initiation or intensification of bronchodilator or corticosteroid therapy

12 months post-surgery
Composite Cardiovascular Outcome
時間枠:12 months post-surgery

Incidence of the Composite Cardiovascular Outcome:

Cardiovascular death; Acute myocardial infarction; Unstable angina; Myocardial revascularization; Acute ischemic stroke (acute cerebrovascular accident); Transient ischemic attack (TIA); Acute heart failure; Hospitalization for decompensated heart failure; New-onset atrial fibrillation or ventricular tachycardia; Initiation or intensification of antiarrhythmic therapy

12 months post-surgery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Alla A. Boshchenko, MD, PhD, DSc、Cardiology Research Institute of Tomsk NRMC
  • 主任研究者:Tatiana P. Kalashnikova, MD, PhD、Cardiology Research Institute of Tomsk NRMC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月29日

一次修了 (推定)

2026年10月30日

研究の完了 (推定)

2028年9月30日

試験登録日

最初に提出

2026年7月29日

QC基準を満たした最初の提出物

2026年7月29日

最初の投稿 (実際)

2026年8月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月11日

QC基準を満たした最後の更新が送信されました

2026年8月6日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する